WO2000037486A1 - Procede de synthese et d'extraction d'aspartame comprenant une phase de deformylation enzymatique - Google Patents

Procede de synthese et d'extraction d'aspartame comprenant une phase de deformylation enzymatique Download PDF

Info

Publication number
WO2000037486A1
WO2000037486A1 PCT/NL1999/000787 NL9900787W WO0037486A1 WO 2000037486 A1 WO2000037486 A1 WO 2000037486A1 NL 9900787 W NL9900787 W NL 9900787W WO 0037486 A1 WO0037486 A1 WO 0037486A1
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
formyl
activity
aspartyl
peptide deformylase
Prior art date
Application number
PCT/NL1999/000787
Other languages
English (en)
Inventor
Peter Jan Leonard Mario Quaedflieg
Theodorus Sonke
Adolf Fritz Volker Wagner
Original Assignee
Holland Sweetener Company V.O.F.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holland Sweetener Company V.O.F. filed Critical Holland Sweetener Company V.O.F.
Priority to AT99962579T priority Critical patent/ATE238344T1/de
Priority to AU18985/00A priority patent/AU1898500A/en
Priority to DE69907266T priority patent/DE69907266T2/de
Priority to KR1020017007869A priority patent/KR20010099875A/ko
Priority to EP99962579A priority patent/EP1140982B1/fr
Publication of WO2000037486A1 publication Critical patent/WO2000037486A1/fr
Priority to US09/886,476 priority patent/US6617127B2/en
Priority to US10/624,640 priority patent/US20040234944A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C07K5/06121—Asp- or Asn-amino acid the second amino acid being aromatic or cycloaliphatic
    • C07K5/0613—Aspartame
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
    • C12P41/007—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures by reactions involving acyl derivatives of racemic amines

Definitions

  • the invention relates to a method for synthesis of -L-aspartyl-L-phenylalanine methyl ester ( ⁇ -APM; aspartame) involving enzymatic deformylation of an N- formyl - ⁇ -L-aspartyl -L-phenylalanine compound.
  • ⁇ -APM aspartame
  • An N- formyl - ⁇ -L-aspartyl-L-phenylalanine compound as meant herein is understood to be either N- formyl - ⁇ -L- aspartyl-L-phenylalanine or its methyl ester (F- ⁇ -AP or F- ⁇ -APM) .
  • the invention also relates to a method for preparation and recovery of ⁇ -APM from either (i) a mixture of N- formyl - ⁇ - and N- formyl - ⁇ -L-aspartyl -L- phenylalanine or (ii) a mixture of N- formyl - ⁇ - and N- formyl- ⁇ -L-aspartyl-L-phenylalanine methyl ester (F- ⁇ - AP or F- ⁇ -APM) by enzymatic deformylation.
  • the invention relates to a simple method for one-pot enzymatic synthesis of ⁇ -APM from N- formyl -L- aspartic acid (F-Asp) and L- or D, L-phenylalanine methyl ester (L- or D,L-PM) also involving an enzymatic deformylation reaction.
  • F-Asp N- formyl -L- aspartic acid
  • L- or D, L-PM L- or D, L-phenylalanine methyl ester
  • the latter combination of simultaneous enzymatic coupling and deformylation reactions has wider and more general applicability.
  • Aspartame ( ⁇ -APM, L,L-form) is known to be a high intensity artificial sweetener, having a sweetness which is about 200x as potent as the sweetness of sucrose, whereas its tast properties are close to those of sucrose.
  • the ⁇ -form of APM does not have sweet taste properties.
  • ⁇ -APM is used for the sweetening of various edible materials. Synthesis methods for ⁇ -APM include chemical syntheses routes (e.g. by coupling of the anhydride of F-Asp with L-Phe or L-PM) which are invariably leading to mixtures of ⁇ - and ⁇ -forms of F-APM in ratios of about 70/30 to 80/20 wt . /wt . ) .
  • the synthesis methods for ⁇ -APM also include enzymatic coupling methods (e.g. by coupling of F-Asp or N- benzyloxy-carbonyl-L-Asp, also known as Z-Asp, with D,L-PM or L-PM) .
  • the enzymatic methods have the clear advantage that they selectively yield the ⁇ -coupled L,L-product in protected form.
  • This patent teaches that penicillin-acylases are not suitable for removal of formyl -groups from oligopeptides .
  • the yield is described to be 20% after 36 hours of reaction at an extremely high concentration of active enzyme as compared to the F- ⁇ -APM (namely 50 U of enzyme and 2 g of F- ⁇ -APM) .
  • active enzyme namely 50 U of enzyme and 2 g of F- ⁇ -APM
  • the method for synthesis of ⁇ -L-aspartyl- L-phenylalanine methyl ester by enzymatic deformylation of an N- formyl - ⁇ -L-aspartyl-L-phenylalanine compound according to the present invention comprises treating N- formyl - ⁇ -L-aspartyl -L-phenylalanine or its methyl ester with an enzyme having formylmethionyl peptide deformylase activity and having as a co- factor bivalent metal ions chosen from the group of group 5 to 11 metals from the periodic system of elements.
  • Bivalent metal ions from the group of group 5 to 11 metals are, for instance, V + , Cr + , Mn + , Fe 2+ , Co + , ⁇ i 2+ , Cu 2+ , Pd 2+ , and Pt 2+ .
  • Mn 2+ , Fe 2+ , Co 2+ and Ni 2+ are preferred.
  • the amount of the bivalent metal ions should be about equivalent to the number of moles of enzyme.
  • the molar ratio between these bivalent metal ions and the number of PDF molecules is in the range of 0.6 to 1.4, preferably of 0.8 to 1.2, and most preferred the amount of bivalent metal ions is equimolar to the enzyme .
  • Recovery of ⁇ -APM from the reaction mixture can be done by any method known to the skilled man.
  • Various methods of crystallisation of aspartame have been described in the literature, e.g. in EP-A-0091787 , EP-A-0399605 and EP-A-0582351.
  • the recovery of ⁇ -APM is done at a pH near the iso-electric point of ⁇ -APM, i.e. at a pH in the range of 3 to 7.
  • the present invention is in particular surprising as there has not been any indication in the state of the art so far that PDF enzymes are also suitable for deformylating terminal N- formyl -L-aspartic acid residues in oligopeptides or dipeptides.
  • Enzymes having formylmethionyl peptide deformylase activity are widely available in nature. Usually they are being described as formylmethionine deformylases . It should be noticed, however, that in the literature also other names are being used instead of the name formylmethionine deformylase; in particular the following names may be mentioned here: (poly) peptide deformylase, N- formylmethionylaminoacyl-tRSTA deformylase, N- formyl -L- methionine amidohydrolase, N- formylmethionyl-aminoacyl- tR ⁇ A amidohydrolase.
  • the native PDF's in nature catalyse the deformylation of the formyl group from the terminal N-methionine residue in nascent polypeptides; more specifically, the PDF's catalyse the hydrolysis of the N-formyl group from the ⁇ -terminal L- methionine residue of nascent polypeptides synthesized by the ribosomal protein synthesis machinery.
  • the native PDF's catalyse the deformylation of the formyl group from the terminal N-methionine residue in nascent polypeptides; more specifically, the PDF's catalyse the hydrolysis of the N-formyl group from the ⁇ -terminal L- methionine residue of nascent polypeptides synthesized by the ribosomal protein synthesis machinery.
  • no other practical applications of these enzymes are known so far. On the contrary, Rajagopalan et al . (Biochem.
  • deformylases have strong sequence preference for methionine at the N-terminus of peptide substrates and to a lesser extent for norleucine at that site. It is thus surprising that these enzymes can be used favourably in the synthesis of ⁇ -APM.
  • the PDF's are obtainable, for instance, from eubacteria, for example Escherichia coli , Bacillus subtilis, Clostridium beij erinckii , Clostridium acetobutylicum, Thermotoga mari tima, Thermus aquaticus, Thermus thermophilus, Calothrix PCC 7601 , Haemophilus influenzae, Bacillus stearothermophilus or Lactococcus lactis .
  • an enzyme from Escherichia coli is used.
  • the inventors have found that the PDF's in order to be able to be used in the synthesis methods according to the present invention require as a co- factor bivalent metal ions chosen from the group of group 5 to 11 metals from the periodic system of elements.
  • reaction conditions for the enzymatic deformylation according to the invention are not very critical. Any suitable solvent system which is inert towards the PDF may be applied; such solvents include aqueous systems (solutions or slurries) or aqueous systems also containing a water-miscible organic solvent which is inert under the reaction conditions. Aqueous systems, however, are preferred. Also the concentration of the N-formyl compound is not critical, and may be for instance in the range of about 10 to 1000 ttiM. It is not necessary that all of the N- formyl compound is dissolved; part of it may be present as a slurry.
  • the concentration of the PDF likewise is not very critical, and usually will be at 0.001 to 100 %, normally less than 30.0 % by weight of the formyl compound, e.g. at about 0.2 mM of PDF.
  • the pH for the reaction preferably is chosen in the range of 3.0 to 9.0, more preferably of 4.0 to 8.0.
  • the temperature is not very critical, and suitably will be in the range of 10 to 50°C, e.g. at about 37°C, but for thermostable PDF enzymes higher temperatures may be applied.
  • PDF- enzyme from E. coli .
  • This has been shown to be a monomeric enzyme having a length of 168 amino acids with a molecular mass of 19197 Dalton as calculated from its amino acid sequence (minus the N-terminal methionine, which is removed by a post -translational modification step) .
  • This enzyme is made up of an active core domain composed of amino acids 1 to 147, and a C- terminal domain of amino acids 148-168; the latter domain, however, is not essential for the deformylase activity.
  • the PDF coding gene from E. coli has been cloned (Mazel et al .
  • One of the measures which are suitable for stabilizing the PDF is ensuring that the PDF's are being handled in an environment having reduced 0 2 content, preferably under anaerobic conditions. Under such conditions almost no reduction of molecular oxygen to hydrogen peroxide takes place, with simultaneous oxidation of the bivalent metal ion, such as Fe 2+ . Reduction of the content of dissolved 0 2 can also be accomplished, by enzymatic removal of thereof, for instance by using a glucose oxidase/catalase system (Rajagopalan, P.T.R., and D. Pei, J. Biol. Chem., 273, No. 35, 22305-22310, (1998)).
  • Stabilisation of PDF's also can be achieved by alternative stabilising measures, namely by the addition/presence of other stabilisation agents, for instance of trialkylphosphine compounds or derivatives thereof; examples of such compouns are triethylphosphine, tributylphosphine and TCEP (tris-(2- carboxyethyl) -phosphine) .
  • these stabilisation agents easily react with H 2 0 2 or other peroxides.
  • inactivation of PDF's also can be prevented by handling the PDF's at higher concentration, for instance at a PDF concentration of at least 0.1 mg of PDF per ml, more preferably of at least 1.0 mg/ml .
  • the upper limit of the concentration of PDF is not critical if practical concentrations are being used.
  • enzymes used according to the method of the invention instead of the enzymes used according to the method of the invention, of course, also whole cells, enzyme preparations, immobilised enzymes, etc. can be applied which are having formylmethionyl peptide deformylase activity.
  • enzyme, PDF, etc. as used herein therefore also include such other forms of active enzyme, including genetically engineered mutants thereof, which for instance have enhanced activity or selectivity in the deformylation reaction.
  • the enzymes to be used can be classified according to standard classification schemes for enzyme activities.
  • a very important group of enzymes having formylmethionyl peptide deformylase activity is classified as EC 3.5.1.27.
  • the enzyme therefore is an enzyme having the activity as described for EC 3.5.1.27 because excellent results are being achieved in the deformylation with such enzymes.
  • the enzyme coded as EC 3.5.1.31 is catalyzing a different reaction, but in the meantime it has been shown that the enzymes known as EC 3.5.1.27 and EC 3.5.1.31 are coded for by exactly the same gene and have the same activity. Therefore, as used herein, the term EC 3.5.1.27 is encompassing not only EC 3.5.1.31, but likewise all other enzymes having the same activity as described for EC 3.5.1.27.
  • A alanine
  • C cysteine
  • E glutamic acid
  • G glycine
  • H histidine
  • L leucine
  • S serine
  • Q glutamine
  • the method of the present invention is carried out using a PDF which is obtainable from E. coli .
  • co- factor bivalent metal ions in the PDF preferably are manganese, iron, cobalt and nickel ions. It has been indicated hereinbefore how such exchange of co- factor bivalent metal ions can be achieved.
  • PMdf ' s are being used which contain Fe and/or Ni 2+ ions in the active site because then highest - In ⁇
  • the stabilisation agent is catalase or a trialkylphosphine compound or derivative, most preferably it is catalase.
  • a further advantage of such use has been found.
  • these enzymes are very regioselective .
  • they have a very high activity for deformylation of F- ⁇ -AP and F- ⁇ -APM, whereas they have no or only low activity for deformylation of F- ⁇ -AP or F- ⁇ -APM.
  • the surprisingly found ⁇ -selectivity of the PDF enzymes according to the invention is used in selectively recovering ⁇ -APM from a mixture of F- ⁇ -APM and F- ⁇ -APM, or in selectively preparing ⁇ -AP from a mixture of F- ⁇ -AP and F- ⁇ -AP, followed by conversion of the ⁇ -AP into ⁇ -APM, and recovering the ⁇ -APM.
  • ⁇ -AP (M) The selective preparation of ⁇ -AP (M) from a mixture of F- ⁇ -AP (M) and F- ⁇ -AP (M) in particular can suitably be used in combination with chemical synthesis methods for AP (M) by formyl -protection routes.
  • the formyl-deprotection step in such routes is troublesome and requires long reaction times and, usually, a further esterification step.
  • a mixture of at least eight compounds (four ⁇ -compounds: ⁇ -APM, ⁇ -AP, ⁇ -AMP and ⁇ - AMPM, and their corresponding ⁇ -compounds; in AMP the methyl ester group is present on the ⁇ -carboxyl function of the L-Asp moiety, and AMPM represents a dimethyl ester) is formed.
  • Recovery of ⁇ -APM in these processes needs to be done through the intermediate selective precipitation and recovery of the ⁇ -APM.
  • HC1 salt whereas the other seven compounds predominantly remain in solution and need to be recycled and reconverted into their starting materials L-Asp and L- Phe (by hydrolysis) and, after recovery thereof, again into ⁇ -APM. This is disadvantageous because of the very long reaction times, relatively low once-through yield of ⁇ -APM and low efficiency on L-Asp and L-Phe due to losses in the recovery.
  • the PDF is an EC 3.5.1.27 enzyme because then excellent results are being achieved. More preferably, the PDF contains the sequences (I) HEXXH, (ii) EGCLS and (m) GXGXAAXQ.
  • the PDF used is obtainable from E. coli , and the bivalent metal ions are manganese, iron, cobalt and nickel ions. It is even more preferred that the bivalent metal ions are iron and/or nickel ions.
  • the bivalent metal ion is Fe 2+ and all the treatments with the PDF enzyme are carried out in the presence of a stabilisation agent.
  • the stabilisation agent is preferably catalase or a trialkylphosphme compound or derivative, and most advantageously it is catalase.
  • the enzymatic deformylation step according to the invention is integrated into a novel one-pot enzymatic synthesis of ⁇ -APM.
  • N- formyl -L-aspartic acid F-Asp
  • thermolysin as the coupling enzyme
  • L- or D L-phenylalanine methyl ester
  • N-F- ⁇ -APM N- formyl- ⁇ -L-aspartyl-L- phenylalanine methyl ester
  • N-F- ⁇ -APM N-F- ⁇ -APM formed by the coupling reaction is deformylated by an enzyme having formylmethionyl peptide deformylase activity (PDF) and having as a co- factor bivalent metal ions chosen from the group of group 5 to 11 metals from the periodic system of elements and being present in the reaction system for the enzymatic coupling reaction.
  • PDF formylmethionyl peptide deformylase activity
  • thermolysin as used here and hereinafter is intended to mean thermolysin, including any mutant thereof, and any other enzyme which has suitable coupling activity for said enzymatic coupling reaction.
  • the ⁇ -APM so formed is recovered after the reaction has proceeded till a conversion of more than 40%. Conversion as meant here relates to the conversion of the L-PM starting in the coupling step to the desired ⁇ -APM endproduct . Without the simultaneous deformylating step the yield of the enzymatic coupling reaction of F-Asp and L- or D,L-PM (which is thermodynamically unfavourable due to the position of the equilibrium of this reaction) is lying strongly on the side of the substrates.
  • the difference in activity towards the protected monomeric and oligomeric compounds is either almost absent (e.g. for PenG-acylases) or opposite, i.e. there is much higher activity for the protected monomeric compound (e.g. for decarbamoylases) .
  • the PDF's as used according to the present invention would be suitable in the methods of the present invention.
  • the PDF ' s as used in the methods of the present invention behave completely different from other deacylating enzymes (or amidohydrolases) .
  • This embodiment of the present invention is in particular surprising as there has not been any indication in the state of the art so far that PDF enzymes are suitable for deformylating terminal N- formyl-L-aspartic acid residues in oligopeptides or dipeptides.
  • the PDF's have significantly different deformylating activities towards N- formyl amino acids and towards (N-terminal) N- formyl oligopeptides.
  • reaction conditions for this third embodiment of the present invention again are not very critical .
  • any suitable solvent system which is inert towards the PDF may be applied; such solvents include aqueous systems (solutions or slurries) or aqueous systems also containing a water-miscible organic solvent which is inert under the reaction conditions.
  • Aqueous systems are preferred.
  • concentration of the N- formyl starting compound (F-Asp) is not critical, and may be for instance in the range of about 10 to 1000 mM. It is not necessary that all of the N- formyl compound is dissolved; part of it may be present as a slurry.
  • the concentration of the PDF likewise is not very critical, and usually will be at 0.001 to 100.0 %, normally less than 30 %, by weight of the formyl compound, e.g. at about 0.2 mM of PDF.
  • the pH for the reaction preferably is chosen in the range of 3.0 to 9.0, more preferably of 4.0 to 8.0 because then ⁇ -APM is formed without any significant formation of by-products and the enzymes used are being maintained at high stability and activity. If the ⁇ -APM formed is precipitated there is even less risk for by-product formation.
  • the temperature is not very critical, and suitably will be in the range of 10 to 50°C, e.g. at about 37°C, but for thermostable PDF enzymes higher temperatures may be applied.
  • the PDF is an enzyme having the activity as described for EC 3.5.1.27.
  • the PDF enzyme contains the sequences of (i) HEXXH, (ii) EGCLS and (iii) GXGXAAXQ.
  • the PDF enzyme has a deformylating activity towards (oligo) peptides with N-formylmethionine at their ⁇ -terminus, which is at least lOx higher, preferably at least lOOx higher, and most preferred at least 200x higher than its deformylating activity towards N- formyl methionine.
  • the deformylation activity of the PDF's in order to select most suitable PDF's, also may be determined for (N-terminal) N- formyl compounds other than the N- formylmethionine (oligo) peptides and their corresponding N- formyl amino acids.
  • the ratio between the deformylating activity values obtained for such other N- formyl (oligo) peptides and amino acids can be taken as an approximate measure for the suitability of the specific PDF in this third embodiment .
  • This preferred embodiment of the invention may even have more general applicability than for the synthesis of ⁇ -APM. It is particularly advantageous when the enzymatic deformylation reaction is simultaneously carried out with the enzymatic coupling of an N- formyl amino acid (in the case of ⁇ -APM synthesis this is F-Asp) and another amino acid or (oligo) peptide which is unprotected at the terminal amino group (in the case of ⁇ -APM synthesis this is L- PM) .
  • the method of the present invention is carried out using a PDF which is obtainable from E. coli .
  • the co-factor bivalent metal ions in the PDF preferably are Mn 2+ , Fe 2+ , Co 2+ and Ni 2+ ions. It has been indicated hereinbefore how such exchange of co- factor bivalent metal ions can be achieved.
  • PDF's are being used which contain Fe 2+ and/or Ni 2+ ions in the active site.
  • the bivalent metal ions are Fe 2+ ions and all treatments with the PDF enzyme are carried out in the presence of a stabilisation agent.
  • the stabilisation agent is catalase or a trialkylphosphine compound or derivative, most preferably it is catalase.
  • thermolysin coupling enzyme which is an endoproteinase
  • the PDF in order to maintain the activity of both the thermolysin coupling enzyme (which is an endoproteinase) and the PDF at a sufficiently high level, taking one or more additional measures may lead to better results. For instance, it may be advisable to prevent any potential proteolytic degradation of the PDF used by thermolysin. In particular, it can be advantageous to use the thermolysin and/or the PDF in immobilized form. Immobilization may be taken care of by any method available to the skilled man. A suitable method is using the enzymes m the form of so-called CLEC ' s ("cross-linked enzyme crystals"). Other methods include use of so-called "crystalline enzyme” thermolysin and PDF.
  • mutants of PDF's may be used which have (a still acceptable, preferably unaltered or even enhanced) activity towards the deformylation reaction but are less prone to deactivation m the presence of thermolysin.
  • These mutants can be generated by a number of different approaches; for instance, by site-directed mutagenesis, site-specifIC random mutagenesis, regio- specific random mutagenesis, and completely random mutagenesis; the latter form of mutagenesis is better known as directed evolution.
  • General applicable methods to perform these different protein engineering approaches are well known to the skilled man.
  • thermolysin can be made having (a still acceptable, but preferably unaltered or even enhanced) coupling activity, but giving less inactivation of the PDF's.
  • thermolysin and the PDF Another suitable method for avoiding mutual deactivation of the thermolysin and the PDF is the use of a physical barrier between both enzymes, which prevents that both enzymes come into direct contact while allowing almost unhindered transport of reactants and products.
  • An example of a suitable physical barrier are dialysis membranes with a cut-off value of about 10 kDa, where the thermolysin is present at one side of the membrane as well as part of the substrates for the coupling reaction, and where the PDF and part of the reaction products are present at the other side thereof .
  • the present invention therefore also relates to novel one-pot syntheses of di- or oligopeptides or derivatives thereof from two starting materials, the first of which is an N- formyl protected amino acid which is capable of undergoing an enzymatic coupling reaction with a second amino acid or derivative thereof, or with a di- or oligo-peptide or derivative thereof, thereby yielding an N- formyl protected reaction compound, wherein the N- formyl protecting group of the first starting material is retained during the enzymatic coupling reaction with the second starting material, whereby said protecting group is cleaved off enzymatically, using an enzyme having formylmethionyl peptide deformylase activity and having as a co- factor bivalent metal ions chosen from the group of group 5 to 11 metals from the periodic system of elements, from the reaction compound at a substantially higher, i.e.
  • An EC 3.5.1.27 PDF(Fe 2+ ) enzyme was isolated from overproducing E. coli cells grown at 30°C in 1.6 1 TB medium for 14-16 hours. About 13 g (wet weight) of cell paste were suspended in 26 ml buffer (20 mM Hepes/KOH, 100 mM KF, pH 7.7 supplemented with 10 ⁇ g/ml catalase from bovine liver (Boehringer Mannheim) and 1 mM AEBSF, disintegrated by sonification (Branson B12, 20 min) at 0°C and centrifuged at 200.000g for 1 hour.
  • the clear supernatant (1.3 g of protein; according to biurete reaction) was mixed with 1.3 ml 10%(w/v) Polymin G-35 (BASF) adjusted to pH 7.7 and centrifuged at 40.000g for 10 minutes. The supernatant was applied to a 20 ml Met-Lys-Sepharose column that had been equilibrated with 20 mM Hepes/KOH, 100 mM KF, 0.2 mM TCEP, pH 7.7.
  • TB medium 12 g/1 of Bacto-Tryptone, Difco; 24 g/1 of yeast extract, Difco; 4 g/1 of glycerole; 2.3 g/1 of KH 2 P0 4 ; 12.5 g/1 of K 2 HP0 4 ) ; Hepes : N-2 -hydroxyethylpiperazine-N' -2 -ethane sulphuric acid;
  • AEBSF 2 -aminoethyl -p-benzene sulphonyl fluoride
  • TCEP tris- (2 -carboxyethyl) -phosphine.
  • T ⁇ BS trinitrobenzene sulphonic acid
  • the amount of (deformylated) compound each time was corrected for the intrinsic amount of free amino compound which was detected without incubation with the PDF. Identification of the reaction compounds was also confirmed by HPLC analysis (as described above) .
  • the results are summarized m table 2.
  • the product yields indicated are the yields after 10 hours of reaction time. It has been shown m case of Examples 1 and 2 that the deformylation reactions can be continued to a conversion of more than 90%.
  • the catalytic properties of the PDF m the deformylation reactions of F- ⁇ -AP and F- ⁇ -APM were determined by performing the reactions of Examples 1 and 2 at various substrate concentrations from 2-140 mM.
  • the following catalytic properties of the enzyme were determined: K M [mM] : Michaelis constant (this is the substrate concentration at which the reaction rate is 50% of the maximum reaction rate observed)
  • k cat [min "1 ] turnover number
  • k cat /K M [M ⁇ sec -1 ] catalytic efficiency (also called: specificity constant)
  • EXAMPLE 1 Use of PDF(Fe 2+ ) for synthesis of ⁇ -APM from F- ⁇ -APM
  • EXAMPLE 2 Use of PDF(Fe 2+ ) for synthesis of ⁇ -AP from F- ⁇ -AP
  • EXAMPLE 3 Use of PDF(Fe 2+ ) for synthesis of ⁇ -APM from F- ⁇ -APM (Note: 100 mM F- ⁇ -APM, 25 mM F- ⁇ -APM) COMPARATIVE EXAMPLE A: Use of PDF(Fe 2+ ) for deformylation of F- ⁇ -APM COMPARATIVE EXAMPLE B: Use of PDF(Fe 2+ ) for deformylation of F- ⁇ -AP COMPARATIVE EXAMPLE C: Use of PDF(Fe 2+ ) for deformylation of F-Asp
  • F- ⁇ -APM 1 g of F- ⁇ -APM was dissolved in 25 ml of distilled water and the pH was adjusted to 6,5 by the addition of 0.1 M aqueous NaOH. Then, 0.2 g of an immobilized penicillin-acylase preparation was added. The reaction mixture was allowed to stand for 48 hours at 37°C. At regular time intervals during the reaction, samples were taken and analyzed by thin layer chromatography using ⁇ -APM as a reference substance. In none of the samples taken, formation of ⁇ -APM from F- ⁇ -APM could be demonstrated.
  • CLEC-thermolysin PeptiCLEC-TR, from Altus Biologies Inc., Cambridge, USA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne un procédé de synthèse d'aspartame comprenant une déformylation enzymatique d'un composé N-formyl-α-L-aspartyl-L-phénylalanine par traitement avec une enzyme possédant une activité déformylase de peptide formylméthionyle et comprenant comme cofacteurs des ions métalliques bivalents des groupes 5 à 11. L'invention concerne également la préparation sélective et l'extraction d'aspartame d'un mélange de composés N-formyl-α- et β-L-aspartyl-L-phénylalanine par traitement avec cette enzyme. L'invention concerne enfin une synthèse enzymatique en récipient unique d'aspartame à partir d'acide N-formyl-L-aspartique et d'un ester méthylique L- ou D,L-phénylalanine faisant intervenir une réaction de déformylation enzymatique simultanément avec une réaction de couplage enzymatique, ainsi qu'une synthèse de di ou oligo-peptides en récipient unique, par des réactions simultanées de couplage enzymatique et de déformylation en général.
PCT/NL1999/000787 1998-12-22 1999-12-20 Procede de synthese et d'extraction d'aspartame comprenant une phase de deformylation enzymatique WO2000037486A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT99962579T ATE238344T1 (de) 1998-12-22 1999-12-20 Synthese und gewinnung von aspartam, unter anwendung eines enzymatischen deformylationsschrittes
AU18985/00A AU1898500A (en) 1998-12-22 1999-12-20 Synthesis and recovery of aspartame involving enzymatic deformylation step
DE69907266T DE69907266T2 (de) 1998-12-22 1999-12-20 Synthese und gewinnung von aspartam, unter anwendung eines enzymatischen deformylationsschrittes
KR1020017007869A KR20010099875A (ko) 1998-12-22 1999-12-20 효소 탈포르밀화 단계를 포함하는 아스파탐의 합성 및회수 방법
EP99962579A EP1140982B1 (fr) 1998-12-22 1999-12-20 Procede de synthese et d'extraction d'aspartame comprenant une phase de deformylation enzymatique
US09/886,476 US6617127B2 (en) 1998-12-22 2001-06-22 Synthesis and recovery of aspartame involving enzymatic deformylation step
US10/624,640 US20040234944A1 (en) 1998-12-22 2003-07-23 Synthesis and recovery of aspartame involving enzymatic deformylation step

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98204373.9 1998-12-22
US11907799P 1999-02-08 1999-02-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/886,476 Continuation US6617127B2 (en) 1998-12-22 2001-06-22 Synthesis and recovery of aspartame involving enzymatic deformylation step

Publications (1)

Publication Number Publication Date
WO2000037486A1 true WO2000037486A1 (fr) 2000-06-29

Family

ID=22382460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1999/000787 WO2000037486A1 (fr) 1998-12-22 1999-12-20 Procede de synthese et d'extraction d'aspartame comprenant une phase de deformylation enzymatique

Country Status (1)

Country Link
WO (1) WO2000037486A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110562A2 (fr) 2011-02-16 2012-08-23 Novozymes A/S Compositions détergentes comprenant des métalloprotéases
WO2012110563A1 (fr) 2011-02-16 2012-08-23 Novozymes A/S Compositions détersives contenant des métalloprotéases
WO2012110564A1 (fr) 2011-02-16 2012-08-23 Novozymes A/S Composition de détergent comprenant des métalloprotéases m7 ou m35
WO2014029819A1 (fr) 2012-08-22 2014-02-27 Novozymes A/S Métalloprotéase dérivée de exiguobacterium
WO2014029821A1 (fr) 2012-08-22 2014-02-27 Novozymes A/S Métalloprotéases dérivées de alicyclobacillus sp.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438201A (en) * 1981-07-01 1984-03-20 Sanraku-Ocean Co., Ltd. Amidohydrolase having ability to depantothenylate an antibiotic
EP0149594A2 (fr) * 1984-01-16 1985-07-24 Monsanto Company Accouplement enzymatique de N-formyl amino-acides et/ou de restes peptidiques
US4668625A (en) * 1984-06-27 1987-05-26 Farmitalia Carlo Erba Process for preparing peptides
US4745067A (en) * 1985-05-02 1988-05-17 Microbial Chemistry Research Foundation L-aminoacylases
WO1996002630A1 (fr) * 1994-07-15 1996-02-01 Eli Lilly And Company Procedes analytiques et de preparation permettant de purifier la phtalylamidase obtenue a partir de xanthobacter agilis
WO1998003664A1 (fr) * 1996-07-19 1998-01-29 Monsanto Company DEFORMYLATION DE PEPTIDES f-MET DANS DES SYSTEMES D'EXPRESSION BACTERIENS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438201A (en) * 1981-07-01 1984-03-20 Sanraku-Ocean Co., Ltd. Amidohydrolase having ability to depantothenylate an antibiotic
EP0149594A2 (fr) * 1984-01-16 1985-07-24 Monsanto Company Accouplement enzymatique de N-formyl amino-acides et/ou de restes peptidiques
US4668625A (en) * 1984-06-27 1987-05-26 Farmitalia Carlo Erba Process for preparing peptides
US4745067A (en) * 1985-05-02 1988-05-17 Microbial Chemistry Research Foundation L-aminoacylases
WO1996002630A1 (fr) * 1994-07-15 1996-02-01 Eli Lilly And Company Procedes analytiques et de preparation permettant de purifier la phtalylamidase obtenue a partir de xanthobacter agilis
WO1998003664A1 (fr) * 1996-07-19 1998-01-29 Monsanto Company DEFORMYLATION DE PEPTIDES f-MET DANS DES SYSTEMES D'EXPRESSION BACTERIENS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAJAGOPALAN ET AL.: "Purification, characterization , and inhibition of peptide deformylase from Escherichia coli.", BIOCHEMISTRY, vol. 36, 1997, pages 13910 - 13918, XP002104855 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110562A2 (fr) 2011-02-16 2012-08-23 Novozymes A/S Compositions détergentes comprenant des métalloprotéases
WO2012110563A1 (fr) 2011-02-16 2012-08-23 Novozymes A/S Compositions détersives contenant des métalloprotéases
WO2012110564A1 (fr) 2011-02-16 2012-08-23 Novozymes A/S Composition de détergent comprenant des métalloprotéases m7 ou m35
WO2014029819A1 (fr) 2012-08-22 2014-02-27 Novozymes A/S Métalloprotéase dérivée de exiguobacterium
WO2014029821A1 (fr) 2012-08-22 2014-02-27 Novozymes A/S Métalloprotéases dérivées de alicyclobacillus sp.
US9315791B2 (en) 2012-08-22 2016-04-19 Novozymes A/S Metalloproteases from alicyclobacillus
US9719054B2 (en) 2012-08-22 2017-08-01 Novozymes A/S Metalloproteases from Alicyclobacillus

Similar Documents

Publication Publication Date Title
CA1059051A (fr) Procede de production d'un peptide
JPH11508452A (ja) ペプチドおよびｎ−カルバモイル保護されたペプチドの新規製造法
US6617127B2 (en) Synthesis and recovery of aspartame involving enzymatic deformylation step
EP0640687B1 (fr) Méthode d'utilisation, d'approvisionement et de transport de l'enzyme protease sous une forme stabilisee
EP0149594A2 (fr) Accouplement enzymatique de N-formyl amino-acides et/ou de restes peptidiques
So et al. Protease-catalyzed tripeptide (RGD) synthesis
WO2000037486A1 (fr) Procede de synthese et d'extraction d'aspartame comprenant une phase de deformylation enzymatique
EP1140982B1 (fr) Procede de synthese et d'extraction d'aspartame comprenant une phase de deformylation enzymatique
JP2007319063A (ja) ジペプチドの製造方法
US5693485A (en) Enzymatic coupling reaction of N-protected-L-aspartic acid and phenylalanine methyl ester
US5002872A (en) Enzyme mediated coupling reactions
EP0768384B1 (fr) Réaction améliorée de couplage enzymatique d'acide L-aspartique N-protégé et d'ester méthylique de phenylalanine
IE52242B1 (en) Preparation of amino protected-l-aspartyl-l-phenylalanine alkyl ester
CA1320923C (fr) Reactions de couplage a mediation enzymatique
JP4856184B2 (ja) オリゴペプチドアミドからオリゴペプチドアルキルエステルへの酵素転化
Murakami et al. Continuous enzymatic production of peptide precursor in aqueous/organic biphasic medium
US7018817B1 (en) Process for the preparation of compounds with enhanced optical purity
EP0269390B1 (fr) Production enzymatique de l'ester alcoylique de L-aspartyl-L-phénylalanine
EP0279832A1 (fr) Procede enzymatique
JPH0634745B2 (ja) Ｎ−保護ペプチドの酵素的合成法
EP0300450B1 (fr) Méthode de production de chlorhydrate de l'ester méthylique d'alpha-L-aspartyl-L-phénylalanine
JPH0525480B2 (fr)
JPS63500491A (ja) Ｎ−ホルミル−ｌ−ペプチドの製造方法
Jakubke Are Proteases Suitable Tools for the Formation of Peptide Bonds?
KR20020015742A (ko) 단백질 가수분해효소를 이용한 아스파탐 전구체의 제조방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99816316.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999962579

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020017007869

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 589555

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09886476

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999962579

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017007869

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1999962579

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017007869

Country of ref document: KR